Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$122.60 ▲ +0.09
(+0.07%)
MKT CAP: $10.19B • VOL: 1.05M
52W L $56 52W H $130
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$103
MEDIAN
$137
MEAN
$140
HIGH
$167
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE KYMR TAPE
KYMR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $148.35 | $140.99 | 2025-02-14 | $111.57 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $154.48 | $144.67 | 2025-02-06 | $115.24 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $139.76 | $134.86 | 2025-01-29 | $117.70 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $125.05 | — | 2025-01-17 | $120.15 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $107.89 | $116.47 | 2025-01-09 | $109.11 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $145.89 | $127.50 | 2024-12-18 | $106.66 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $118.92 | $123.83 | 2024-12-04 | $114.02 | -4.3% | 48% | C |